Literature DB >> 14576917

[Pharmaceutical care for drug-related problems in inpatients].

M Q Gorgas Torner1, E Odena Estradé, F Pastor Solernou.   

Abstract

UNLABELLED: Drug therapy-induced high morbidity results in pharmacists participating in the prevention and solution of drug-related problems (DRPs).
OBJECTIVE: To assess DRP prevalence amongst inpatients, and the clinical results derived from pharmaceutical intervention.
METHODS: DRPs detected during 6 months at Hospital Comarcal de Sant Bernabé were recorded and classified, and their severity established. Pharmaceutical intervention was evaluated by using two codes: impact and clinical significance. Interventions were reassessed by another pharmacist and a physician, and the degree of agreement was calculated.
RESULTS: The prevalence of DRPs amongst inpatients was 10.8%. A total of 425 DRPs was detected, with a mean of 1.51 DRPs/patient. The highest percentage involved inappropriate drugs (26%), overdosing (22%), and inadequate dosing (22%). Eighty-four percent of DRPs were a severity level 2. Drugs mainly involved were antibiotics (21.6%), anti-ulcer agents (21.8%), and analgesic-anti-inflammatory compounds (8.1%). In all, 58% of interventions impacted on treatment effectiveness, and 42% on toxicity. Intervention acceptance was 91%. Seventy percent of interventions were appropriate and highly significant. The percentage of agreements in reassessments exceeded 88%.
CONCLUSIONS: Pharmaceutical care allows DRPs to be prevented and solved. Methodology validation makes it safer in daily practice.

Entities:  

Mesh:

Year:  2003        PMID: 14576917

Source DB:  PubMed          Journal:  Farm Hosp        ISSN: 1130-6343


  1 in total

1.  Prescribing errors intercepted by clinical pharmacists in paediatrics and obstetrics in a tertiary hospital in Spain.

Authors:  Cecilia M Fernandez-Llamazares; Miguel-Ángel Calleja-Hernández; Silvia Manrique-Rodríguez; Cristina Pérez-Sanz; Esther Durán-García; María Sanjurjo-Sáez
Journal:  Eur J Clin Pharmacol       Date:  2012-03-06       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.